INmune Bio Inc (NASDAQ:INMB) shares, rose in value on Thursday, April 16, with the stock price up by 0.14% to the previous day’s close as strong demand from buyers drove the stock to $7.32.
Actively observing the price movement in the last trading, the stock closed the session at $7.31, falling within a range of $7.14 and $7.5135. The value of beta (5-year monthly) was 1.876. Referring to stock’s 52-week performance, its high was $12.72, and the low was $4.32. On the whole, INMB has fluctuated by -11.91% over the past month.
With the market capitalization of INmune Bio Inc currently standing at about $167.85 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-26.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that INMB’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of INMB currently trading nearly -3.68% and -9.47% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 46.72, while the 7-day volatility ratio is showing 7.62% which for the 30-day chart, stands at 9.50%. Furthermore, INmune Bio Inc (INMB)’s beta value is 1.63, and its average true range (ATR) is 0.69.
A comparison of INmune Bio Inc (INMB) with its peers suggests the former has fared considerably weaker in the market. INMB showed an intraday change of 0.14% in last session, and over the past year, it shrunk by -20.00%%.
Data on historical trading for INmune Bio Inc (NASDAQ:INMB) indicates that the trading volumes over the past 10 days have averaged 0.27 and over the past 3 months, they’ve averaged 345.31K. According to company’s latest data on outstanding shares, there are 22.28 million shares outstanding.
Nearly 28.90% of INmune Bio Inc’s shares belong to company insiders and institutional investors own 27.18% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 6.06 million shares as on 2025-03-31, resulting in a short ratio of 23.33. According to the data, the short interest in INmune Bio Inc (INMB) stood at 3285.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 5.42 million. The stock has risen by 56.75% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the INMB stock heading into the next quarter.
